2 suspended. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Suspended 2 |
Follow Triple Negative Breast Neoplasms: new trials by email Literature Review of Triple Negative Breast Neoplasms trials Research Report on Triple Negative Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC JS001，an engineered anti-PD-1 antibody, Nab-Paclitaxel, Placebo - Triple Negative Breast Cancer | Phase 3 | Suspended | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 375 | 2018-12-21 | 2019-08-08 |
| A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer EndoTAG-1, Paclitaxel, Gemcitabine Hydrochloride - Triple-Negative Breast Cancer | Phase 3 | Suspended | SynCore Biotechnology Co., Ltd. | 420 | 2016-11-23 | 2023-04-26 |
Breast Diseases (2) · Breast Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Paclitaxel (2) · 130-nm albumin-bound paclitaxel (1) · Gemcitabine (1) · MBT-0206 (1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · SynCore Biotechnology Co., Ltd. (1)
China (1) · Taiwan (1)